RT Journal Article
T1 Progression-free survival at 2 years post-autologous transplant: a surrogate end point for overall survival in follicular lymphoma.
A1 Jiménez-Ubieto, Ana
A1 Grande, Carlos
A1 Caballero, Dolores
A1 Yáñez, Lucrecia
A1 Novelli, Silvana
A1 Hernández, Miguel T
A1 Manzanares, María
A1 Arranz, Reyes
A1 Ferreiro, José Javier
A1 Bobillo, Sabela
A1 Mercadal, Santiago
A1 Galego, Andrea
A1 Jiménez, Javier López
A1 Moraleda, José María
A1 Vallejo, Carlos
A1 Albo, Carmen
A1 Pérez, Elena
A1 Marrero, Carmen
A1 Magnano, Laura
A1 Palomera, Luis
A1 Jarque, Isidro
A1 Coria, Erika
A1 Rodriguez, Antonia
A1 Martín, Alejandro
A1 López-Guillermo, Armando
A1 Salar, Antonio
A1 Lahuerta, Juan José
A1 GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) cooperative study group, 
K1 Autologous Stem Cell Trasplantation
K1 CR 30
K1 Follicular Lymphoma
K1 PFS 24
K1 Rituximab
AB Overall survival (OS) is the gold-standard end point for studies evaluating autologous stem cell transplantation (ASCT) in follicular lymphoma (FL), but assessment may be elusive due to the lengthy disease course. We analyzed the validity of two earlier end points, proposed in the setting of first-line chemo-/immunotherapy, as surrogates for OS-progression-free survival (PFS) status at 24 months (PFS24) and complete response at 30 months (CR30) post-ASCT. We also have investigated the clinical features of patients with early progression after ASCT. Data were available for 626 chemosensitive FL patients who received ASCT between 1989 and 2007. Median follow-up was 12.2 years from ASCT. In the PFS24 analysis, 153 (24%) patients progressed within 24 months and 447 were alive and progression-free at 24 months post-ASCT (26 who died without disease progressions within 24 months were excluded). Early progression was associated with shorter OS (hazard ratio [HR], 6.8; P = 0.00001). In the subgroup of patients who received an ASCT in the setting or relapse after being exposed to rituximab, the HR was 11.3 (95% CI, 3.9-30.2; P 
YR 2017
FD 2017-10-26
LK https://hdl.handle.net/10668/25019
UL https://hdl.handle.net/10668/25019
LA en
DS RISalud
RD Apr 6, 2025